MX2012012486A - Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones). - Google Patents

Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones).

Info

Publication number
MX2012012486A
MX2012012486A MX2012012486A MX2012012486A MX2012012486A MX 2012012486 A MX2012012486 A MX 2012012486A MX 2012012486 A MX2012012486 A MX 2012012486A MX 2012012486 A MX2012012486 A MX 2012012486A MX 2012012486 A MX2012012486 A MX 2012012486A
Authority
MX
Mexico
Prior art keywords
preparation
solutions
colloidal silica
pharmaceutical compositions
preparations
Prior art date
Application number
MX2012012486A
Other languages
English (en)
Other versions
MX338043B (es
Inventor
Viktor Lvovich Limonov
Konstantin Valentinovich Gaidul
Aleksandr Valerevich Dushkin
Original Assignee
Viktor Lvovich Limonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viktor Lvovich Limonov filed Critical Viktor Lvovich Limonov
Publication of MX2012012486A publication Critical patent/MX2012012486A/es
Publication of MX338043B publication Critical patent/MX338043B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a farmacología, medicina, veterinaria e industria farmacéutica, concretamente a composiciones farmacéuticas para la preparación de disoluciones para infusión de preparaciones antimicrobianas que potencian la eficacia terapéutica de productos farmacéuticos antimicrobianos, durante el procedimiento de preparación de sus disoluciones inmediatamente antes de preparar infusiones intravenosas y los procedimientos de producción de principios farmacéuticos compuestos originales. Las composiciones farmacéuticas ofrecidas para la preparación de disoluciones para inyección de todas las preparaciones antimicrobianas sometidas a prueba que contienen el polvo finamente disperso de sílice coloidal nanoestructurada, aumentan de manera fiable su eficacia terapéutica cuando se trata septicemia fulminante de animales de prueba, provocada por Staphylococcus aureus, Escherichia coli, Pseudonionas aeruginosa y Candida albicans. Las composiciones farmacéuticas ofrecidas para la preparación de disoluciones de preparaciones antibacterianas y antifúngicas para infusiones intravenosas (NaC1:sílice coloidal y dextrosa:sílice coloidal) tienen una acción potenciadora significativa clínicamente importante sobre su potencial terapéutico cuando se tratan enfermedades inflamatorias e infecciosas malignas, en comparación con disolventes tradicionales (prototipos de la invención).
MX2012012486A 2011-11-22 2012-10-26 Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones). MX338043B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011147170/15A RU2476206C1 (ru) 2011-11-22 2011-11-22 Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)

Publications (2)

Publication Number Publication Date
MX2012012486A true MX2012012486A (es) 2013-05-21
MX338043B MX338043B (es) 2016-03-30

Family

ID=46940397

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012486A MX338043B (es) 2011-11-22 2012-10-26 Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones).
MX2015005804A MX364061B (es) 2011-11-22 2012-10-26 Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015005804A MX364061B (es) 2011-11-22 2012-10-26 Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones).

Country Status (21)

Country Link
US (2) US9889158B2 (es)
EP (1) EP2596783B1 (es)
JP (1) JP5568114B2 (es)
CN (2) CN107913250B (es)
AU (1) AU2012211402B2 (es)
BR (1) BR102012020929B1 (es)
CA (1) CA2792574C (es)
CY (1) CY1120810T1 (es)
DK (1) DK2596783T3 (es)
ES (1) ES2685222T3 (es)
HR (1) HRP20181274T1 (es)
HU (1) HUE039112T2 (es)
LT (1) LT2596783T (es)
MX (2) MX338043B (es)
PL (1) PL2596783T3 (es)
PT (1) PT2596783T (es)
RS (1) RS57578B1 (es)
RU (1) RU2476206C1 (es)
SI (1) SI2596783T1 (es)
TR (1) TR201810244T4 (es)
UA (1) UA105260C2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2476206C1 (ru) 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
GR1008554B (el) * 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
MX2021009679A (es) 2019-02-22 2021-09-10 Catalent Uk Swindon Zydis Ltd Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
JPS60169431A (ja) * 1984-02-14 1985-09-02 Nippon Zenyaku Kogyo Kk β−ラクタム環を有する化合物を含有する安定な抗菌剤及びその製造法
IT1243180B (it) 1990-07-31 1994-05-24 Nunzio Rapisarda Uso della fosfomicina e dei suoi sali come agente cicatrizzante topico
CN1071076A (zh) * 1991-09-26 1993-04-21 丛繁滋 双黄连气雾剂的制备方法
FR2687071B1 (fr) 1992-02-10 1995-06-23 Exsymol Sa Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
JP3435664B2 (ja) * 1999-12-08 2003-08-11 ヤンセンファーマ株式会社 口腔内速崩壊型錠剤及びその製造方法
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
WO2003063877A1 (en) * 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
ES2282628T3 (es) * 2002-04-23 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicon farmaceutica que contiene particulas de lamotrigina de morfologia definida.
JP4695390B2 (ja) 2002-08-09 2011-06-08 アクゾ ノーベル コーティングス インターナショナル ビー ヴィ 酸キャップされた四級化ポリマー及びそのようなポリマーを含む組成物
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
EA013864B1 (ru) * 2008-08-29 2010-08-30 Лимонова, Анастасия Викторовна Способ повышения антимикробной активности цефалоспориновых антибиотиков
EA021875B1 (ru) 2010-09-20 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного и ранозаживляющего действия для наружного применения, способ ее получения
EA021876B1 (ru) * 2010-09-20 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
RU2476206C1 (ru) 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)

Also Published As

Publication number Publication date
CN107913250B (zh) 2021-01-22
MX338043B (es) 2016-03-30
MX364061B (es) 2019-04-11
CN107913250A (zh) 2018-04-17
ES2685222T3 (es) 2018-10-05
DK2596783T3 (en) 2018-08-27
CY1120810T1 (el) 2019-12-11
EP2596783B1 (en) 2018-06-06
AU2012211402A1 (en) 2013-06-06
AU2012211402B2 (en) 2013-12-05
TR201810244T4 (tr) 2018-08-27
HUE039112T2 (hu) 2018-12-28
CA2792574C (en) 2017-01-17
RS57578B1 (sr) 2018-11-30
UA105260C2 (ru) 2014-04-25
LT2596783T (lt) 2018-09-25
EP2596783A1 (en) 2013-05-29
US9889158B2 (en) 2018-02-13
BR102012020929B1 (pt) 2019-08-06
CN103126995B (zh) 2018-01-12
US20150283172A1 (en) 2015-10-08
BR102012020929A2 (pt) 2013-10-29
CA2792574A1 (en) 2013-05-22
SI2596783T1 (sl) 2018-10-30
NZ601748A (en) 2012-12-21
CN103126995B8 (zh) 2018-04-06
PL2596783T3 (pl) 2018-11-30
CN103126995A (zh) 2013-06-05
RU2476206C1 (ru) 2013-02-27
US9844566B2 (en) 2017-12-19
HRP20181274T1 (hr) 2018-11-02
US20140105936A1 (en) 2014-04-17
PT2596783T (pt) 2018-10-09
JP5568114B2 (ja) 2014-08-06
JP2013107870A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
JP2014505733A5 (es)
WO2011115969A3 (en) Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form
MX338043B (es) Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones).
BRPI1010948A2 (pt) Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais.
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
WO2016060517A3 (ko) 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
JP2014520892A5 (es)
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
JP2015526463A5 (es)
MY184630A (en) Tylosin derivatives and method for preparation thereof
EA201100735A1 (ru) Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
MX2012010707A (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
EA201001507A1 (ru) Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
EA201100733A1 (ru) Фармацевтическая композиция для лечения туберкулеза и других инфекций, способ ее получения
AR093922A1 (es) Composicion farmaceutica que contiene telmisartan
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
ZHU et al. Research Progress in Antibiotic Adjuvant and Antibiotics in Antibacterial Aspects
CN103444730A (zh) 一种生物源杀菌组合物
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
EA201100736A1 (ru) Фармацевтическая композиция антимикробного действия для парентерального применения, способ ее получения
RU2011148433A (ru) Способ лечения субклинического мастита у коров

Legal Events

Date Code Title Description
FG Grant or registration